Literature DB >> 11803185

Central pontine myelinolysis.

Christian Lampl1, Kambiz Yazdi.   

Abstract

Central pontine myelinolysis (CPM) is a demyelinating disease of the pons often associated with demyelination of other areas of the central nervous system (CNS). The term 'osmotic demyelinization syndrome' is used for pontine and extrapontine myelinolysis. In this paper, we are concerned with CPM although the extrapontine one is based on the same pathogenesis. Both share the diagnostic methods, and their prevention and therapy are the same. The etiology and pathogenesis of this disorder are unclear and will be discussed. However, almost all cases of CPM are related to severe diseases. Chronic alcoholism is still the most common underlying condition of CPM patients. In the literature, 174 cases of CPM have been reported in alcoholics since 1986, which is equivalent to an incidence of 39.4%. Likewise, 95 cases of CPM following the correction of hyponatremia have been documented since 1986 (21.5%). The role of hyponatremia and its correction will be outlined in the discussion of the pathogenesis of CPM. The third largest group of CPM cases are liver transplant patients (17.4%), with the development of CPM being attributed to the immunosuppressive agent cyclosporine in particular. Depending on the involvement of other CNS structures, the clinical picture can vary considerably. The large-scale introduction of magnetic resonance imaging has increasingly facilitated the antemortem diagnosis of CPM, although the radiological findings lag behind and do not necessarily correlate with the clinical picture. As yet, there is no specific therapy of choice. A number of therapeutic approaches have been tested and although they have not been compared with regard to their rate of success, they have all led to a substantial improvement in the prognosis of CPM. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11803185     DOI: 10.1159/000047939

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  37 in total

1.  Osmotic demyelination syndrome: variable clinical and radiologic response to intravenous immunoglobulin therapy.

Authors:  Santosh B Murthy; Shahram Izadyar; Megha Dhamne; Joseph S Kass; Corey E Goldsmith
Journal:  Neurol Sci       Date:  2012-04-11       Impact factor: 3.307

2.  Possible case of peripheral osmotic demyelination syndrome.

Authors:  P J Serrano-Castro; G Alonso-Verdegay; G López-Martínez; A Arjona-Padillo; J R Callejón; V M Olmedo; P Guardado-Santervás; A Huete-Hurtado; J Olivares-Romero; C Naranjo Fernández
Journal:  BMJ Case Rep       Date:  2009-02-02

3.  Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis.

Authors:  Céline Odier; Dang Khoa Nguyen; Michel Panisset
Journal:  J Neurol       Date:  2010-02-11       Impact factor: 4.849

4.  Central pontine myelinolysis: historical and mechanistic considerations.

Authors:  Michael D Norenberg
Journal:  Metab Brain Dis       Date:  2010-02-25       Impact factor: 3.584

5.  Central pontine and extrapontine myelinolysis secondary to fast correction of severe hyponatremia and hypokalemia in an alcoholic patient.

Authors:  Ahmad Ghaith Tarakji; Ahmad Raed Tarakji; Uzma Shaheen
Journal:  Int Urol Nephrol       Date:  2012-11-22       Impact factor: 2.370

Review 6.  Demyelinating diseases.

Authors:  S Love
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

Review 7.  Vasopressin receptor antagonists in patients with chronic heart failure.

Authors:  R De Vecchis; C Cantatrione; D Mazzei
Journal:  Herz       Date:  2016-09-15       Impact factor: 1.443

8.  Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging.

Authors:  Kimberly A Ruzek; Norbert G Campeau; Gary M Miller
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study.

Authors:  Isabelle Morard; Yvan Gasche; Mark Kneteman; Christian Toso; Ariane Mentha; Glenda Meeberg; Gilles Mentha; Norman Kneteman; Emiliano Giostra
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

10.  Microarray analysis of mouse brain gene expression following acute ethanol treatment.

Authors:  Julie A Treadwell; Shiva M Singh
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.